Logo image of ARDX

ARDELYX INC (ARDX) Stock Fundamental Analysis

NASDAQ:ARDX - Nasdaq - US0396971071 - Common Stock - Currency: USD

5.505  +0.05 (+1.01%)

After market: 5.51 +0 (+0.09%)

Fundamental Rating

3

Overall ARDX gets a fundamental rating of 3 out of 10. We evaluated ARDX against 566 industry peers in the Biotechnology industry. ARDX has a bad profitability rating. Also its financial health evaluation is rather negative. ARDX is valued quite expensively, but it does show have an excellent growth rating.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

In the past year ARDX has reported negative net income.
In the past year ARDX has reported a negative cash flow from operations.
In the past 5 years ARDX always reported negative net income.
ARDX had a negative operating cash flow in each of the past 5 years.
ARDX Yearly Net Income VS EBIT VS OCF VS FCFARDX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

With an excellent Return On Assets value of -8.98%, ARDX belongs to the best of the industry, outperforming 86.75% of the companies in the same industry.
ARDX has a Return On Equity of -22.58%. This is amongst the best in the industry. ARDX outperforms 84.81% of its industry peers.
Industry RankSector Rank
ROA -8.98%
ROE -22.58%
ROIC N/A
ROA(3y)-22.18%
ROA(5y)-43.77%
ROE(3y)-43.52%
ROE(5y)-79.37%
ROIC(3y)N/A
ROIC(5y)N/A
ARDX Yearly ROA, ROE, ROICARDX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

With an excellent Gross Margin value of 84.85%, ARDX belongs to the best of the industry, outperforming 87.10% of the companies in the same industry.
ARDX's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for ARDX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 84.85%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.98%
GM growth 5Y-0.87%
ARDX Yearly Profit, Operating, Gross MarginsARDX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

More info and screens

3

2. Health

2.1 Basic Checks

ARDX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ARDX has more shares outstanding
ARDX has more shares outstanding than it did 5 years ago.
The debt/assets ratio for ARDX is higher compared to a year ago.
ARDX Yearly Shares OutstandingARDX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M
ARDX Yearly Total Debt VS Total AssetsARDX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

Based on the Altman-Z score of 1.45, we must say that ARDX is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of ARDX (1.45) is better than 70.32% of its industry peers.
ARDX has a Debt/Equity ratio of 0.87. This is a neutral value indicating ARDX is somewhat dependend on debt financing.
The Debt to Equity ratio of ARDX (0.87) is worse than 77.56% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.87
Debt/FCF N/A
Altman-Z 1.45
ROIC/WACCN/A
WACC10.16%
ARDX Yearly LT Debt VS Equity VS FCFARDX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M

2.3 Liquidity

A Current Ratio of 4.58 indicates that ARDX has no problem at all paying its short term obligations.
ARDX has a Current ratio (4.58) which is comparable to the rest of the industry.
ARDX has a Quick Ratio of 4.31. This indicates that ARDX is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of ARDX (4.31) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 4.58
Quick Ratio 4.31
ARDX Yearly Current Assets VS Current LiabilitesARDX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 45.67% over the past year.
Looking at the last year, ARDX shows a very strong growth in Revenue. The Revenue has grown by 168.07%.
ARDX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 129.15% yearly.
EPS 1Y (TTM)45.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%116.67%
Revenue 1Y (TTM)168.07%
Revenue growth 3Y220.85%
Revenue growth 5Y129.15%
Sales Q2Q%237.95%

3.2 Future

ARDX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 52.30% yearly.
ARDX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 21.91% yearly.
EPS Next Y-51.3%
EPS Next 2Y92.68%
EPS Next 3Y88.81%
EPS Next 5Y52.3%
Revenue Next Year15.2%
Revenue Next 2Y24.51%
Revenue Next 3Y25.54%
Revenue Next 5Y21.91%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
ARDX Yearly Revenue VS EstimatesARDX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
ARDX Yearly EPS VS EstimatesARDX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 2 -2

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ARDX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ARDX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ARDX Price Earnings VS Forward Price EarningsARDX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ARDX Per share dataARDX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1

4.3 Compensation for Growth

A more expensive valuation may be justified as ARDX's earnings are expected to grow with 88.81% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y92.68%
EPS Next 3Y88.81%

More info and screens

0

5. Dividend

5.1 Amount

ARDX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ARDELYX INC

NASDAQ:ARDX (4/30/2025, 8:00:01 PM)

After market: 5.51 +0 (+0.09%)

5.505

+0.05 (+1.01%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-20 2025-02-20/bmo
Earnings (Next)05-01 2025-05-01/amc
Inst Owners64.68%
Inst Owner Change0.27%
Ins Owners1.84%
Ins Owner Change9.5%
Market Cap1.31B
Analysts86.67
Price Target11.17 (102.91%)
Short Float %12.99%
Short Ratio6.56
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)208.75%
Min EPS beat(2)94%
Max EPS beat(2)323.5%
EPS beat(4)4
Avg EPS beat(4)119.85%
Min EPS beat(4)26.89%
Max EPS beat(4)323.5%
EPS beat(8)6
Avg EPS beat(8)73.44%
EPS beat(12)10
Avg EPS beat(12)549.88%
EPS beat(16)10
Avg EPS beat(16)409.91%
Revenue beat(2)2
Avg Revenue beat(2)7.36%
Min Revenue beat(2)3.56%
Max Revenue beat(2)11.16%
Revenue beat(4)4
Avg Revenue beat(4)17.29%
Min Revenue beat(4)3.56%
Max Revenue beat(4)30.48%
Revenue beat(8)7
Avg Revenue beat(8)32.64%
Revenue beat(12)10
Avg Revenue beat(12)29.91%
Revenue beat(16)13
Avg Revenue beat(16)51.73%
PT rev (1m)8.86%
PT rev (3m)1.64%
EPS NQ rev (1m)-0.16%
EPS NQ rev (3m)-42.05%
EPS NY rev (1m)-5.47%
EPS NY rev (3m)-268.01%
Revenue NQ rev (1m)0.05%
Revenue NQ rev (3m)-5.43%
Revenue NY rev (1m)1.29%
Revenue NY rev (3m)0.21%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.93
P/FCF N/A
P/OCF N/A
P/B 7.57
P/tB 7.57
EV/EBITDA N/A
EPS(TTM)-0.16
EYN/A
EPS(NY)-0.25
Fwd EYN/A
FCF(TTM)-0.19
FCFYN/A
OCF(TTM)-0.19
OCFYN/A
SpS1.4
BVpS0.73
TBVpS0.73
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -8.98%
ROE -22.58%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 84.85%
FCFM N/A
ROA(3y)-22.18%
ROA(5y)-43.77%
ROE(3y)-43.52%
ROE(5y)-79.37%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.98%
GM growth 5Y-0.87%
F-Score2
Asset Turnover0.77
Health
Industry RankSector Rank
Debt/Equity 0.87
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 49.01%
Cap/Sales 0.3%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.58
Quick Ratio 4.31
Altman-Z 1.45
F-Score2
WACC10.16%
ROIC/WACCN/A
Cap/Depr(3y)26.96%
Cap/Depr(5y)45.67%
Cap/Sales(3y)0.23%
Cap/Sales(5y)4.69%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)45.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%116.67%
EPS Next Y-51.3%
EPS Next 2Y92.68%
EPS Next 3Y88.81%
EPS Next 5Y52.3%
Revenue 1Y (TTM)168.07%
Revenue growth 3Y220.85%
Revenue growth 5Y129.15%
Sales Q2Q%237.95%
Revenue Next Year15.2%
Revenue Next 2Y24.51%
Revenue Next 3Y25.54%
Revenue Next 5Y21.91%
EBIT growth 1Y55.82%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year76.47%
EBIT Next 3Y99.5%
EBIT Next 5Y62.75%
FCF growth 1Y49.12%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y50.06%
OCF growth 3YN/A
OCF growth 5YN/A